Aurora Cannabis Inc. announced its financial and operational results for the first quarter of fiscal 2026, ending June 30, 2025. The company delivered another strong quarter of sustained, profitable growth, with total net revenue increasing 17% year-over-year to $98.0 million.
Global medical cannabis net revenue rose 37% to $64.8 million, driven by an 85% growth in international markets, particularly Germany and Poland. This segment contributed 66% of Aurora's consolidated net revenue and 91% of adjusted gross profit.
Adjusted EBITDA increased 209% to $10.8 million, and the company generated positive free cash flow of $9.2 million, a 42% increase from the prior year period. For Q2 2026, Aurora expects consolidated net revenue to increase year-over-year, primarily driven by 8% to 12% growth in its Global Medical Cannabis segment, and anticipates continued strong positive adjusted EBITDA and positive annual free cash flow for the second consecutive year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.